Journal of Neuro-Oncology

, Volume 105, Issue 2, pp 127–134 | Cite as

Primary intraocular lymphoma: a review

  • Gregory S. Vosganian
  • Saskia Boisot
  • Kathrin I. Hartmann
  • William R. Freeman
  • Robert W. Sharpe
  • Prabhakar Tripuraneni
  • Alan Saven
Topic Review

Abstract

Primary intraocular lymphoma (PIOL) is a rare, non-Hodgkin lymphoma considered to be a subtype of primary central nervous system lymphoma. We describe a 65-year-old woman who presented to the Hematology/Oncology Clinic at Scripps Clinic, La Jolla, California, who was diagnosed with bilateral PIOL without systemic disease. She enjoyed a 16-month remission but ultimately recurred in the brain. We reviewed the literature and present a discussion of the diagnostic criteria for PIOL and current strategies for treating PIOL in immunocompetent patients.

Keywords

Intraocular lymphoma Non-Hodgkin lymphoma Central nervous system lymphoma Therapies Autologous transplantation Chemotherapy Chemo-immunotherapy 

References

  1. 1.
    Pe’er J, Hochberg FH, Foster CS (2009) Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 17:299–306PubMedCrossRefGoogle Scholar
  2. 2.
    Levy-Clarke GA, Chan CC, Nussenblatt RB (2005) Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 19:739–749 viiiPubMedCrossRefGoogle Scholar
  3. 3.
    Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 242:901–913PubMedCrossRefGoogle Scholar
  4. 4.
    Bardenstein DS (1998) Intraocular lymphoma. Cancer Control 5:317–325PubMedGoogle Scholar
  5. 5.
    Hormigo A, Abrey L, Heinemann MH, DeAngelis LM (2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126:202–208PubMedCrossRefGoogle Scholar
  6. 6.
    Choi JY, Kafkala C, Foster CS (2006) Primary intraocular lymphoma: a review. Semin Ophthalmol 21:125–133PubMedCrossRefGoogle Scholar
  7. 7.
    Faia LJ, Chan CC (2009) Primary intraocular lymphoma. Arch Pathol Lab Med 133:1228–1232PubMedGoogle Scholar
  8. 8.
    Sen HN, Bodaghi B, Hoang PL, Nussenblatt R (2009) Primary intraocular lymphoma: diagnosis and differential diagnosis. Ocul Immunol Inflamm 17:133–141PubMedCrossRefGoogle Scholar
  9. 9.
    Raparia K, Chang CC, Chevez-Barrios P (2009) Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med 133:1233–1237PubMedGoogle Scholar
  10. 10.
    Kim SK, Chan CC, Wallace DJ (2005) Management of primary intraocular lymphoma. Curr Oncol Rep 7:74–79PubMedCrossRefGoogle Scholar
  11. 11.
    Margolis L, Fraser R, Lichter A, Char DH (1980) The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 45:688–692PubMedCrossRefGoogle Scholar
  12. 12.
    Chan CC, Wallace DJ (2004) Intraocular lymphoma: update on diagnosis and management. Cancer Control 11:285–295PubMedGoogle Scholar
  13. 13.
    Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T (1986) Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 57:1273–1275PubMedCrossRefGoogle Scholar
  14. 14.
    Strauchen JA, Dalton J, Friedman AH (1989) Chemotherapy in the management of intraocular lymphoma. Cancer 63:1918–1921PubMedCrossRefGoogle Scholar
  15. 15.
    Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMedGoogle Scholar
  16. 16.
    Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044–1049PubMedCrossRefGoogle Scholar
  17. 17.
    Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538PubMedCrossRefGoogle Scholar
  18. 18.
    Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730–4735PubMedCrossRefGoogle Scholar
  19. 19.
    de Smet MD, Stark-Vancs V, Kohler DR, Smith J, Wittes R, Nussenblatt RB (1996) Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 121:442–444PubMedGoogle Scholar
  20. 20.
    Mason JO, Fischer DH (2003) Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology 110:1241–1244PubMedCrossRefGoogle Scholar
  21. 21.
    Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16:3000–3006PubMedGoogle Scholar
  22. 22.
    Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA (1997) Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 115:1152–1156PubMedGoogle Scholar
  23. 23.
    Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe’er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716PubMedCrossRefGoogle Scholar
  24. 24.
    Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O’Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD (2007) Intraocular use of rituximab. Eye (Lond) 21:1524–1527CrossRefGoogle Scholar
  25. 25.
    Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749PubMedGoogle Scholar
  26. 26.
    Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512–2518PubMedCrossRefGoogle Scholar
  27. 27.
    Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151–4156PubMedCrossRefGoogle Scholar
  28. 28.
    van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2098) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC. 1 phase III randomized intergroup study. J Clin Oncol 28:2853–2858CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Gregory S. Vosganian
    • 1
  • Saskia Boisot
    • 2
  • Kathrin I. Hartmann
    • 3
  • William R. Freeman
    • 3
  • Robert W. Sharpe
    • 2
  • Prabhakar Tripuraneni
    • 4
  • Alan Saven
    • 1
  1. 1.Division of Hematology/OncologyScripps ClinicLa JollaUSA
  2. 2.Division of HematopathologyScripps ClinicLa JollaUSA
  3. 3.The Division of Ophthalmology, Shiley Eye Center/Jacobs Retina CenterUniversity of California-San DiegoLa JollaUSA
  4. 4.Division of Radiation/OncologyScripps Clinic and Green HospitalLa JollaUSA

Personalised recommendations